171 results about "Lipid particle" patented technology

The instant disclosure relates to lipid particles that harbor cationic lipids, the particles found to be capable of delivering associated cargoes - particularly nucleic acid cargoes when formulated as nucleic acid-lipid particles - intracellularly to skin tissue cells when administered topically to a subject. The instant disclosure provides compositions comprising such lipid particles, optionally in association with a therapeutic agent (e.g., a therapeutic mRNA and / or nucleic acid controller system), as well as methods and kits for delivering a lipid particle-associated therapeutic agent and / or for treating or preventing a disease or disorder, e.g., a skin disease or disorder, in a subject, using one or more lipid particle compositions provided herein.

Certain embodiments of the invention provide a cationic lipid of formula (I):wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and / or administering the lipid particles.

Disclosed herein are a peptoid compound and a peptoid conjugate such as a peptoid-lipid conjugate, and preparation methods therefor and the use thereof in a small molecule drug and nucleic acid delivery. Further disclosed herein are a lipid particle containing the peptoid-lipid conjugate, such as a liposome and a lipid nanoparticle, and a small molecule drug and / or a nucleic acid delivery composition containing the peptoid-lipid conjugate or the lipid particle. The peptoid-lipid conjugate, lipid particle, and small molecule drug and / or nucleic acid delivery composition that can be used for the small molecule drug and nucleic acid delivery of the present invention enable highly efficient compounding, protection, intracellular and targeted delivery and release of the small molecule drug and biomolecules, such as nucleic acids, in tissues and organs both in vitro and in vivo.

The invention discloses a multilevel liver targeting drug delivery system based on ionizable amino lipid and a preparation method thereof, the system comprises the following components: target modified ionizable amino lipid, ionizable amino lipid, auxiliary lipid and structural lipid in a molar ratio of (10-30): (30-60): (5-40): (15-55), according to the system, nano lipid particles exist in a water-in-oil-in-water nano emulsion form; wherein the ionizable ammonia lipid is a compound with a structure as shown in a formula (I). The system is suitable for delivering nucleic acid, protein and other active pharmaceutical ingredients to the liver so as to improve the accuracy and treatment effect of drug delivery and reduce the side effects of non-target organs.

The present disclosure relates to an imidazole lipid and a use thereof. Specifically, provided are a compound represented by formula I or a salt thereof, and a lipid particle or a pharmaceutical composition containing the compound. The compound can be used as a delivery system, and is used for preparing drugs for preventing and / or treating cancers, infectious diseases, autoimmune diseases, neurodegenerative diseases, inflammation, etc. The definition of each group in formula (I) is as described in the description.

The present invention addresses the problem of providing: a method for delivering a nucleic acid to immune cells and an agent for delivering a nucleic acid to immune cells, which are both capable of delivering the nucleic acid to both an immune cell that has been subjected to an activation treatment and an immune cell that has not been subjected to an activation treatment; and a method for delivering a nucleic acid to immune cells and an agent for delivering a nucleic acid to immune cells, which are both capable of encapsulating a nucleic acid in a simple manner without a dedicated device. The present invention provides a method for delivering a nucleic acid to immune cells, the method comprising: a step A for preparing lipid particles not containing any nucleic acids, by using an ionizable lipid, a non-ionized lipid, and a lipid having a nonionic polymer; a step B for preparing nucleic acid-containing lipid particles by mixing the nucleic acid with the lipid particles not containing any nucleic acids; and a step C for bringing the nucleic acid-containing lipid particles into contact with immune cells (excluding in vivo delivery methods).

Provided herein are methods of repeated administration of a lipid particle or viral vector, such as for delivery of a payload gene, to a subject.

The present disclosure relates to a hydrogel ink comprising a lipid particle, a polynucleotide supported within the lipid particle, and a bio-ink. In one embodiment, the lipid particles comprise extracellular vesicles. The disclosure also relates to hydrogels thereof and their use in treating neurological diseases or conditions or regenerating soft tissue.

The invention relates to a QS-21 loaded nano adjuvant as well as a preparation method and application thereof. According to the nano adjuvant, the biodegradable polymer, cholesterol and cationic lipid entrapped QS-21 are utilized to form solid lipid particles in an O / W mode, the solid lipid particles have good dispersity, the surfaces of the solid lipid particles are positively charged, and the solid lipid particles can adsorb negatively charged antigen protein to prepare a nano adjuvant vaccine. The cholesterol in the nano adjuvant vaccine can be combined with the QS-21, so that entrapment of the QS-21 can be better realized, the safety and the stability of the nano adjuvant vaccine are improved, and the nano adjuvant vaccine has a wide application prospect in prevention of virus infection.

In this specification, in an aspect, compositions, methods, kits and systems are disclosed relating to the efficient delivery of a freight (e.g., a therapeutic freight) to cells, for example, for in vivo delivery. More specifically, the delivery vehicle is a lipid-containing particle comprising (a) a human endogenous retrovirus (HERV) envelope protein, a humanized envelope protein, or a non-immunogenic membrane fusion molecule, (b) a combinatorial protein comprising a plasma membrane-localized protein, and (c) a freight.

Disclosed herein are complex lipid particles encapsulating one or more exogenous peptides, polypeptides, or proteins, as well as methods of producing a complex lipid formulation comprising an exogenous peptide, polypeptide, or protein. Also, disclosed herein are modified plant messenger packs (PMPs) formulation encapsulating one or more exogenous peptides, polypeptides, or proteins, and methods of producing a modified PMP formulation comprising an exogenous peptide, polypeptide, or protein.

The present invention relates to compositions comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of the nucleic acid in a lipid bilayer. The present invention further relates to said compositions for use in preventing and / or treating disease, particularly for use in preventing and / or treating cancer. The present invention further relates to methods for producing compositions comprising said nucleic acid-lipid particles.

Disclosed herein are compositions for use in a variety of agricultural methods, the compositions comprising a plurality of naturally derived lipid particles comprising a phospholipid, a non-polar lipid, and a surface modifier, and further comprising a biologically active substance.

The present disclosure relates to a novel drug delivery system, which comprises a lipid particle and a modified red blood cell. The present disclosure also relates to preparation of the drug delivery system and therapeutic use thereof.

A prediction device (100) comprises: an information acquisition unit (102) that acquires a condition for preparing lipid particles that are composed of any of a phospholipid, an anionic lipid, and a cationic lipid, and a constituent lipid of the lipid particles; a trained model (103) that predicts the particle size distribution of the lipid particles from the acquired condition for preparing the lipid particles and the acquired constituent lipid of the lipid particles; and an output unit (104) that outputs the particle size distribution of the lipid particles predicted by the trained model (103).

The present disclosure provides compositions capable of delivering a load (including therapeutic agents, e.g., RNA) to organs or tissues other than the liver, lung and spleen (e.g., brain, heart, kidney and muscular tissue). More specifically, the composition comprises a plurality of lipid particles comprising an agent, a cationic lipid, and an ionizable lipid.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

An object of the present invention is to provide a lipid particle that can be produced without using a PEG-modified lipid, or that exhibits higher drug effects, safety, or stability than those of a lipid particle produced using a PEG-modified lipid; or that has immunokinetics different from those of a lipid particle produced using a PEG-modified lipid. A lipid particle comprising an ionized lipid, a phospholipid, and a sterol as lipid components of the lipid particle, and a modified polysaccharide containing a hydrophobic group.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described wherein: the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises a buffer solution having a pH of from about 6.5 to about 8; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and nucleic acids. Methods of making the aqueous dispersions, nucleic acid-lipid particles, methods of making them using the aqueous dispersions, and their use in medicine are disclosed.

To provide a technique for delivering an active substance to the surface of a target cell.SOLUTION: According to one embodiment, a particle-bound lipid particle includes a biodegradable lipid particle, a particle, and active substances, wherein the particle is bound to an outer surface of the lipid particle, and the active substances are bound to a surface of the particle.SELECTED DRAWING: Figure 1

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

This invention belongs to the field of nanocarrier and immunotherapy technology, specifically relating to a lipid nanoparticle targeting tumor-associated macrophages, a combined delivery method, and its application in tumor immunotherapy. The lipid nanoparticles targeting CD206 tumor-associated macrophages constructed in this invention are used for efficient in vivo delivery of multifunctional nucleic acid molecules, achieving immune regulation, gene editing, and anti-tumor therapy. This invention achieves targeted delivery and multifunctional synergistic effects through lipid particle design, nucleic acid sequence design, and in vitro and in vivo functional verification. Through in vivo delivery of ipLNPs, macrophages can simultaneously achieve: 1) expression of anti-PD-L1 antibodies, blocking immunosuppressive signals; 2) expression of HER2-CAR structures, enhancing phagocytosis and killing ability against tumors; and 3) remodeling of the tumor immune microenvironment through CRISPR / Cas9-mediated FN1 knockout. The lipid nanoparticles constructed using this invention can solve the problem of insufficient targeting of immune cells in the tumor microenvironment by traditional LNP delivery systems.

A carboxylic acid-type lipid can accelerate adhesion or aggregation of platelets even if the carboxylic acid-type lipid does not carry a protein involved in adhesion or aggregation of platelets or a peptide corresponding to an active site of the protein; a lipid particle and a lipid membrane each include the carboxylic acid-type lipid; and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane. A carboxylic acid-type lipid is selected from carboxylic acid-type lipids represented by formulas (I) to (VI), a lipid particle includes the carboxylic acid-type lipid, a lipid membrane includes the carboxylic acid-type lipid, and a platelet aggregation accelerating agent, a platelet adhesion accelerating agent, a hemostatic agent and a platelet substitute each include the carboxylic acid-type lipid, the lipid particle or the lipid membrane.

The invention belongs to the field of biological agents, and particularly relates to a dihydromyricetin nano-composite emulsion and a preparation method and application thereof.The dihydromyricetin nano-composite emulsion is prepared from, by weight, 0.5%-3.0% of dihydromyricetin, 2.0%-8.0% of a hydrophilic core solvent, 12.5%-25.5% of a lipid carrier of a bidirectional hydrophilic structure and 63.5%-85.0% of an outer water phase, the preparation method comprises the following steps: completely dissolving DHM in a hydrophilic core solvent, wrapping the DHM in a natural or synthetic lipid carrier with a bidirectional hydrophilic structure to form a water-in-oil nano-emulsion, and dispersing the water-in-oil nano-emulsion in an external water phase by utilizing the bidirectional hydrophilicity of the lipid carrier to form a novel composite emulsion with the particle size of 10-500 nanometers. The defects in the prior art are overcome, the solubility of the DHM can be greatly improved, the normal-temperature stability of the DHM is remarkably improved, the DHM lipid particles can reach the nanoscale and are not prone to segregation, the permeability of the DHM is obviously improved, and the bioavailability of the DHM is improved.

According to one embodiment, there is provided a method of producing a gene modification T cell (CAR-T cells) which expresses a chimeric antigen receptor (CAR). This method includes stimulating a cell population containing a T cell with an antibody which activates the T cell, bringing the cell population into contact with a nucleic acid-introducing carrier, wherein the nucleic acid-introducing carrier containing a lipid particle, a first nucleic acid and containing a CAR gene, and a second nucleic acid containing a transposase gene encapsulated in the lipid particle, and culturing the cell population after the contacting.

The present invention relates to drug delivery vehicles comprising micronized particles that include an active lipid agent, and in particular to micronized lipid particles that comprise an ether lipid such as sn-1-O-eicosanyl-sn-2-palmitoyl-glycerol and its isomers.